Primary Biliary Cholangitis Treatment Market Size to Exceed USD 1,388.5 Mn by 2032

The Primary Biliary Cholangitis Treatment Market, estimated at USD 769.4 Mn in 2025, is expected to exhibit a CAGR of 8.8% and reach USD 1,388.5 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Primary biliary cholangitis is an autoimmune disease that affects the small bile ducts of the liver. The disease causes the bile ducts to become inflamed and scarred, preventing them from working properly. Common symptoms include itching, jaundice, and fatigue. Treatment options primarily focus on relieving symptoms and slowing disease progression.

The Global Primary Biliary Cholangitis Treatment Market is driven by increasing research and development activities to develop novel treatment options. Furthermore, the market growth is supported by rising awareness about the disease through patient advocacy groups and government initiatives. Various government and non-profit organizations conduct awareness programs to spread information about symptoms and available treatment options for primary biliary cholangitis. This is increasing the diagnosis rate globally and thus fuelling demand for treatment.

Global Primary Biliary Cholangitis Treatment Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), that first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the global economies, social behaviors, and healthcare of every country in the world.

The COVID-19 pandemic affected the global economy in three main ways:  by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regards to the transportation of drugs from one place to another.

The COVID-19 had a negative impact on the global primary biliary cholangitis treatment market, as the supply and demand of medicines were hampered due to COVID-19. For instance, on January 8, 2025, EY, a global leader in assurance, consulting, strategy, transactions, and tax services, in an article stated that the COVID-19 pandemic was a global disruption across trade, finance, health, and education systems, businesses. The companies who responded to the survey stated that they were fully prepared for the pandemic. Serious disruptions affected 57% of companies, with 72% reporting a negative effect.

Global Primary Biliary Cholangitis Treatment Market: Key Developments

In November 2025, GSK plc., a multinational pharmaceutical and biotechnology company, announced further progression in its R&D pipeline with presentation of data for linerixibat, an investigational product for the potential treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).

On November 1 2025, CymaBay Therapeutics, Inc., a biopharmaceutical company, announced that two-year safety and efficacy results of seladelpar for primary biliary cholangitis (PBC) have been published in Alimentary Pharmacology & Therapeutics.

On October 23 2025, CymaBay Therapeutics, Inc., announced that the U.S. Food and Drug Administration (FDA) has revised the originally granted Breakthrough Therapy Designation for seladelpar to now reflect treatment of primary biliary cholangitis (PBC) including pruritus in adults without cirrhosis or with compensated cirrhosis.

Browse 24 Market Data Tables and 28 Figures spread through 128 Pages and in-depth TOC on “Global Primary Biliary Cholangitis Treatment Market”- Forecast to 2032 by Treatment Type (Ursodeoxycholic Acid (UDCA), Obeticholic Acid (Ocaliva), Others (Fibrates (Tricor), etc.) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/primary-biliary-cholangitis-treatment-market-2555

Key Takeaways of the Global Primary Biliary Cholangitis Treatment Market:

• The global primary biliary cholangitis treatment market is expected to exhibit a CAGR of 8.8% during the forecast period. Increasing adoption of inorganic growth strategies, such as research and development activities by key players in the market to expand product portfolio, is expected to drive the segment growth over the forecast period. For instance, in January 2025, COUR Pharmaceuticals, a biotechnology company, announced the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to the Company's investigational therapy CNP-104 for the treatment of Primary Biliary Cholangitis.
• Among Treatment Type, Ursodeoxycholic Acid (UDCA) segment is estimated to hold a dominant position in the global primary biliary cholangitis treatment market over the forecast period, owing to increasing research and development activities by key players in the market. For instance, in September 2025, according to a study published by Springer Nature, an academic publishing company, stated a new research titled “Treatment of Primary Biliary Cholangitis: Early Prediction of Inadequate Response to Ursodeoxycholic Acid in Patients with PBC”
• Among region, North America is expected to be the dominant region in the global primary biliary cholangitis treatment market, owing to increasing product approvals by regulatory authorities which is expected to drive the segment growth over the forecast period. For instance, on May 16, 2025, Intercept Pharmaceuticals, Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the fixed-dose combination of obeticholic acid (OCA) and bezafibrate, a peroxisome proliferator-activated receptor (PPAR) agonist, for the potential treatment of individuals with primary biliary cholangitis (PBC).
• Major players operating in the global primary biliary cholangitis treatment market include Intercept Pharmaceuticals, Inc., Highlight Therapeutics, S.L., GSK plc., Bristol-Myers Squibb and Company, Enanta Pharmaceuticals, NW Biotherapeutics, Merck & Co Inc., Ipsen Pharma, Johnson & Johnson, GENFIT, Ironwood Pharmaceuticals, Inc., Novartis AG, COUR Pharmaceuticals, Kaken Pharmaceutical Co., Ltd.